Share issue in Faron Pharmaceuticals Ltd. (FI) — EUR 7.1 million

Carnegie acted as sole bookrunner in Faron Pharmaceuticals’ share issue of 2,491,998 shares at a subscription price of EUR 2.85 per share.
Faron Pharmaceuticals is a clinical stage biopharmaceutical company developing novel treatments for medical conditions with significant unmet needs caused by dysfunction of our immune system. The Company currently has a pipeline based on the receptors involved in regulation of immune response in oncology, organ damage and bone marrow regeneration.